Biodexa Pharmaceuticals plc (BDRX) Debt by Year
Biodexa Pharmaceuticals plc carried $0 in long-term debt against $11.5M in cash and equivalents at the end of fiscal year 2025. The change in long-term debt from the prior fiscal year is not meaningful, because that figure was zero or negative. The table below carries 11 fiscal years, from 2015 to 2025, and the quarters Biodexa Pharmaceuticals plc has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
BDRX Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0-100.0% | $1.1M-86.5% | $8.4M+318.7% | $2.0M-10.1% | $2.2M |
| Cash & Equivalents | $11.5M+449.1% | $2.1M-72.5% | $7.6M+122.2% | $3.4M-74.8% | $13.6M+31.7% | $10.3M-28.9% | $14.5M+384.9% | $3.0M-83.3% | $17.9M-17.8% | $21.7M-8.9% | $23.9M |
BDRX Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q2'256-K | Q4'2420-F | Q2'246-K | Q4'2320-F | Q2'236-K | Q4'2220-F | Q2'226-K | Q4'2120-F | Q4'2020-F | Q4'1920-F | Q4'1820-F |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $0n/m | $687K+161.5% | $0n/m | $263K-45.6% | $0n/m | $483K+189.2% | $0n/m | $167K | $0n/m | $0n/m | $0-100.0% | $1.1M-86.5% |
| Cash & Equivalents | $11.5M+449.1% | $5.5M-13.3% | $2.1M-72.5% | $6.4M-3.8% | $7.6M+122.2% | $6.6M+3.4% | $3.4M-74.8% | $6.4M | $13.6M+31.7% | $10.3M-28.9% | $14.5M+384.9% | $3.0M-83.3% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Biodexa Pharmaceuticals plc financials
Frequently Asked Questions
What was Biodexa Pharmaceuticals plc's long-term debt in fiscal year 2025?
Biodexa Pharmaceuticals plc carried $0 in long-term debt against $11.5M in cash and equivalents at the end of fiscal year 2025.
How fast is Biodexa Pharmaceuticals plc's long-term debt growing?
Biodexa Pharmaceuticals plc (BDRX) reported $0 in long-term debt in fiscal year 2024 and $0 in long-term debt in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.
How has Biodexa Pharmaceuticals plc's long-term debt changed over the years?
Across the 11 fiscal years this page covers, Biodexa Pharmaceuticals plc (BDRX) long-term debt went from $2.2M in fiscal year 2015 to $0 in fiscal year 2025.
What was Biodexa Pharmaceuticals plc's long-term debt in the most recent quarter?
Biodexa Pharmaceuticals plc (BDRX) reported $0 in long-term debt in Q4 2025. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
What does long-term debt mean on a financial statement?
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Biodexa Pharmaceuticals plc (BDRX) reported on that line in every period on record.